Image

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Lipoprotein(a) \[Lp(a)\] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommend that Lp(a) be measured at least once in every adult's lifetime, however routine Lp(a) testing rates remains infrequent.

The aim of this study is to assess the impact of implementation strategies (IStr) designed to increase the adoption of Lp(a) testing in routine practice, ultimately leading to more individuals being tested in secondary care. This, in turn, is expected to result in the identification and enhanced management of Cardiovascular Disease (CVD) risk patients with elevated Lp(a).

Eligibility

Inclusion Criteria:

Each cluster within this study has a set of inclusion criteria. In addition, to be eligible for inclusion in this study, all the following criteria at the cluster-level must be met:

Inclusion criteria for centers:

  1. Lp(a) testing is available in this center and reimbursed.
  2. Capacity to increase Lp(a) testing in relevant patient groups (according to the defined patient eligibility criteria).
  3. Low and/or inconsistent Lp(a) testing rate(number of eligible patients tested for Lp(a)/number of eligible patients seen) \<15%.
  4. Willingness to fulfill research requirements, e.g., repurposing existing clinic data for research etc.
  5. Seeing a defined number of eligible patients per year based on the sample size required for the study.
  6. Availability of local infrastructure and data interoperability.

Inclusion criteria for HCP survey participants:

1\. CV specialists or other HCPs managing and accessing CV risk at their respective centers (cardiology units or equivalent).

Electronic records are eligible for assessment in this study if they meet all the following criteria:

  1. ICF and/or ICF waiver will be sought prior to abstraction of electronic patient records.
  2. Patients attending at least one SOC visit during the pre-defined time intervals (12 months prior to index date and 0-6 months, 7-12 months and 13-24 months post-index).
  3. Previous Lp(a) testing:
    1. Patients with an Lp(a) test recorded before the index date will be included in the baseline assessment, which covers the 12 months prior to the index date.
    2. For post-index assessments at 6-, 12- and 24-months after the index date, patients with an Lp(a) test recorded before the index date will be excluded.
  4. Over 18 years of age and qualify for Lp(a) testing according to local practice.

Exclusion Criteria:

Exclusion criteria at center cluster-level includes:

  1. Centers with no access to Lp(a) testing.
  2. Centers where Lp(a) testing is not reimbursed.

Electronic records will not be assessed for:

1\. Patients that have undergone Lp(a) testing prior to index date (for the post-index assessment)

Study details
    Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice

NCT07508007

Novartis Pharmaceuticals

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.